Leerink upgraded Vertex Pharmaceuticals (VRTX) to Outperform from Market Perform with a $456 price target
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals: Strong Market Position and Growth Potential Drive Buy Rating
- Vertex Pharmaceuticals announces CASGEVY reimbursement agreement in Italy
- Vertex Pharmaceuticals: Strong Buy Rating Backed by Promising Pipeline and Strategic Positioning
- Vertex Pharmaceuticals Positioned for Growth with FDA Support for Non-Opioid Analgesics
- FDA Draft Guidance Boosts Vertex Pharmaceuticals’ Prospects for Non-Opioid Analgesics